Julius Höhne Selected Research

Mental Disorders (Mental Disorder)

12/2018

Excessive release of endogenous neuropeptide Y into cerebrospinal fluid after treatment of spontaneous subarachnoid haemorrhage and its possible impact on self-reported neuropsychological performance - results of a prospective clinical pilot study on good-grade patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julius Höhne Research Topics

Disease

17	Neoplasms (Cancer) 01/2024 - 01/2013
7	Glioma (Gliomas) 01/2022 - 04/2013
6	Brain Neoplasms (Brain Tumor) 01/2022 - 04/2013
4	Meningioma (Meningiomas) 06/2020 - 12/2013
3	Residual Neoplasm 01/2023 - 01/2018
3	Glioblastoma (Glioblastoma Multiforme) 01/2019 - 08/2018
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 06/2021 - 05/2018
2	Aneurysm (Aneurysms) 01/2020 - 12/2018
2	Pain (Aches) 12/2018 - 06/2018
2	Neoplasm Metastasis (Metastasis) 06/2018 - 01/2017
1	Astrocytoma (Pilocytic Astrocytoma) 01/2022
1	Brain Ischemia (Cerebral Ischemia) 06/2021
1	Ganglioglioma 07/2020
1	Spinal Epidural Hematoma 07/2020
1	Intracranial Aneurysm (Cerebral Aneurysm) 01/2020
1	Epidermal Cyst (Sebaceous Cyst) 06/2019
1	Hemorrhage 12/2018
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 12/2018
1	Mental Disorders (Mental Disorder) 12/2018
1	Intracranial Vasospasm 12/2018
1	Seizures (Absence Seizure) 08/2018
1	Hypotension (Low Blood Pressure) 08/2018
1	Empyema 05/2018
1	Wounds and Injuries (Trauma) 05/2018
1	Infarction (Infarctions) 05/2018
1	Hematoma 05/2018
1	Neurologic Manifestations (Neurological Manifestations) 01/2018
1	Spinal Cord Neoplasms (Spinal Cord Tumors) 12/2017
1	Suppuration 04/2017
1	Abscess 01/2016
1	Brain Abscess (Abscess, Brain) 01/2016
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 09/2015
1	Ischemic Stroke 01/2013
1	Edema (Dropsy) 01/2013
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2013

Drug/Important Bio-Agent (IBA)

17	Fluorescein (Funduscein)FDA LinkGeneric 01/2024 - 04/2013
3	GadoliniumIBA 01/2023 - 01/2018
2	Coloring Agents (Dyes)IBA 12/2021 - 01/2018
2	AcidsIBA 12/2021 - 04/2013
2	Fluorescent Dyes (Fluorescent Probes)IBA 12/2021 - 01/2019
2	Polymethyl Methacrylate (Sol)IBA 06/2020 - 05/2018
2	Capsules (Microcapsules)IBA 04/2017 - 01/2016
1	Calcitonin Gene-Related PeptideIBA 06/2021
1	Vasodilator Agents (Vasodilators)IBA 06/2021
1	Neuropeptide YIBA 12/2018
1	EnzymesIBA 12/2018
1	Vasoconstrictor AgentsIBA 12/2018
1	Tyrosine (L-Tyrosine)FDA Link 01/2018
1	TitaniumIBA 12/2013

Therapy/Procedure

3	Craniotomy 06/2019 - 01/2013
2	Lasers (Laser) 01/2024 - 01/2021
2	Intravenous Administration 01/2022 - 01/2016
2	Operative Surgical Procedures 07/2020 - 04/2013
2	Decompression 07/2020 - 06/2018
2	Endoscopes 01/2020 - 01/2019
2	Decompressive Craniectomy 09/2015 - 01/2013
1	Radiotherapy 03/2021
1	Drug Therapy (Chemotherapy) 03/2021
1	Aftercare (After-Treatment) 12/2018
1	Surgical Decompression 06/2018
1	Laminectomy 06/2018
1	Reoperation 05/2018
1	Anesthesia 01/2017